Metabolic & obesity · Phase III

Top sponsors

• Takeda 35 programs
• NovoThirteen 25 programs
• Eli Lilly and 20 programs
• Regeneron UK 12 programs
• Boehringer Ingelheim 10 programs
• Novo Nordisk A/S 10 programs
• AstraZeneca 9 programs
• LEXICON PHARMACEUTICALS 8 programs
• Eli Lilly and 6 programs
• HOFFMANN-LA ROCHE 6 programs
• George Institute for 5 programs
• Kailera Therapeutics 5 programs

1. METFORMIN , DAPAGLIFLOZIN

   Eli Lilly Co.

   Type 2 Diabetes

   phase 3 · small molecule · active

   1 trial →

2. MGL-3196

   Madrigal Pharmaceuticals EU Limited

   NASH - Nonalcoholic Steatohepatitis

   phase 3 · small molecule · active

   1 trial →

3. MGL-3196-11

   Madrigal Pharmaceuticals EU Limited

   Non-Alcoholic Steatohepatitis (NASH)

   phase 3 · small molecule · active

   1 trial →

4. MGL-3196-19

   Madrigal Pharmaceuticals EU Limited

   Non-alcoholic Steatohepatitis (NASH) Cirrhosis

   phase 3 · small molecule · active

   1 trial →

5. MHICC-2021-001

   The George Institute

   Type 2 diabetic patients with no prior cardiovascular (CV) events

   phase 3 · small molecule · active

   1 trial →

6. Maridebart cafraglutide

   Amgen

   Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

   phase 3 · small molecule · active

   1 trial →

7. Metformin

   AstraZeneca

   Type 2 Diabetes

   phase 3 · small molecule · completed

   1 trial →

8. Metformin on top of intensive insulin therapy

   Takeda

   Type 2 Diabetes Mellitus

   phase 3 · small molecule · completed

   1 trial →

9. Metformin plus pioglitazone

   The First People's Hospital of Lianyungang

   Type 2 Diabetes

   phase 3 · small molecule · active

   1 trial →

10. Mibavademab

    Regeneron UK Limited

    Monogenic Obesity

    phase 3 · small molecule · active

    1 trial →

11. Muraglitazar

    Bristol-Myers Squibb

    Diabetes, Type 2

    phase 3 · small molecule · completed

    1 trial →

12. N1T-MC-MALO

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 · small molecule · active

    1 trial →

13. NN1436-7724

    NovoThirteen

    Type 2 Diabetes

    phase 3 · small molecule · active

    1 trial →

14. NN1436-8182

    NovoThirteen

    Type 1 Diabetes

    phase 3 · small molecule · active

    1 trial →

15. NN1535-8377

    NovoThirteen

    Type 2 diabetes

    phase 3 · small molecule · active

    1 trial →

16. NN8022-4392

    NovoThirteen

    Obesity

    phase 3 · small molecule · active

    1 trial →

17. NN9388-4895

    NovoThirteen

    Type 2 diabetes

    phase 3 · small molecule · active

    1 trial →

18. NN9388-7637

    NovoThirteen

    Type 2 diabetes

    phase 3 · small molecule · active

    1 trial →

19. NN9388-7741

    NovoThirteen

    Type 2 Diabetes

    phase 3 · small molecule · active

    1 trial →

20. NN9490-8021

    NovoThirteen

    Obesity

    phase 3 · small molecule · active

    1 trial →

21. NN9490-8024

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 · small molecule · active

    1 trial →

22. NN9490-8025

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 · small molecule · active

    1 trial →

23. NN9490-8026

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 · small molecule · active

    1 trial →

24. NN9490-8028

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 · small molecule · active

    1 trial →

25. NN9490-8266

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 · small molecule · active

    1 trial →

26. NN9490-8293

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 · small molecule · active

    1 trial →

27. NN9490-8294

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 · small molecule · active

    1 trial →

28. NN9490-8559

    NovoThirteen

    Obesity

    phase 3 · small molecule · active

    1 trial →

29. NN9535-4352

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 · small molecule · active

    1 trial →

30. NN9833-8242

    NovoThirteen

    Overweight and obesity

    phase 3 · small molecule · active

    1 trial →

31. NN9833-8243

    NovoThirteen

    Overweight and obesity

    phase 3 · small molecule · active

    1 trial →

32. NN9838-4608

    NovoThirteen

    Overweight and obesity

    phase 3 · other · active

    1 trial →

33. NN9838-4609

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 · small molecule · active

    1 trial →

34. NN9838-7749

    NovoThirteen

    Obesity

    phase 3 · small molecule · active

    1 trial →

35. NN9838-7859

    NovoThirteen

    Obesity

    phase 3 · small molecule · active

    1 trial →

36. NN9924-4437

    NovoThirteen

    Type 2 diabetes

    phase 3 · small molecule · active

    1 trial →

37. NN9931-4553

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 · small molecule · active

    1 trial →

38. NNC0487-0111

    Novo Nordisk A/S

    Obesity

    phase 3 · small molecule · active

    1 trial →

39. OBEZ-303

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 · small molecule · active

    1 trial →

40. OPC-262

    KYOWA KIRIN AUSTRALIA PTY LTD

    Type 2 Diabetes

    phase 3 · small molecule · completed

    1 trial →

41. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · active

    2 trials →

42. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 3 · small molecule · terminated

    1 trial →

43. ORMD-0801 (qd)

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    2 trials →

44. ORMD-0801 8 mg

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · active

    1 trial →

45. Oral semaglutide

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

46. Orforglipron

    Eli Lilly and Company

    Type 2 Diabetes

    phase 3 · small molecule · completed

    1 trial →

47. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 · small molecule · active

    1 trial →

48. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    2 trials →

Frequently asked questions